Passage Bio and Remix Therapeutics Agree to Merge Into One Company
The two biotech firms will combine under the Remix Therapeutics name to advance small molecule therapies that target RNA processing at the disease source.
Passage Bio and Remix Therapeutics have reached a merger agreement that will consolidate the two biotechnology companies under a single corporate identity. The combined entity will operate as Remix Therapeutics, signaling a strategic pivot toward Remix's core scientific platform rather than a blended approach from both organizations.
At the heart of the deal is Remix's pipeline of novel small molecule therapies, which are designed to reprogram RNA processing — a relatively nascent but rapidly evolving area of drug development. Unlike conventional approaches that target proteins after they have been produced, RNA-processing therapies aim to intervene earlier in the biological cascade, addressing the drivers of disease closer to their molecular origin.
Read more UK Tribunal Clears $4bn Apple iCloud Class Action to Proceed →
The merger reflects a broader industry trend of smaller biotech companies consolidating resources and research focus in a challenging capital environment. By uniting under Remix's scientific identity, the combined company signals confidence in the RNA-modulation space as a durable therapeutic frontier rather than a speculative bet.
The strategic logic is clear: Passage Bio brings organizational infrastructure and capital markets experience, while Remix contributes what the companies frame as a differentiated and proprietary scientific approach. Together, they aim to accelerate a pipeline that could eventually offer treatment options for conditions where existing therapies fall short or do not yet exist.
The deal underscores how biotech dealmaking increasingly centers on platform-level science — acquiring or merging around foundational technologies capable of generating multiple drug candidates — rather than single-asset gambles. Investors and analysts watching the RNA therapeutics space will likely scrutinize how the combined Remix Therapeutics allocates resources across its inherited pipeline. Continue reading at GlobalNewswire.
